Vivani Medical ( (VANI) ) has issued an announcement.
Vivani Medical reported significant progress in 2024, transitioning to a clinical-stage biotechnology company with successful milestones in its NPM-115 and NPM-139 programs. The company completed full enrollment in the LIBERATE-1 study and announced promising preclinical data for NPM-139, securing $8.25 million in equity financing to support operations into 2026. Vivani also plans to spin off its subsidiary, Cortigent, to focus on its core drug implant business. Financial results for 2024 showed a decrease in net loss, attributed to staffing reductions and reduced use of outside services.
More about Vivani Medical
Vivani Medical, Inc. is a biopharmaceutical company focused on developing miniaturized, ultra long-acting drug implants for chronic weight management in obese or overweight patients. The company’s lead products include NPM-115 (exenatide implant) and NPM-139 (semaglutide implant), targeting once or twice-yearly dosing to transform chronic weight management treatment.
YTD Price Performance: -7.50%
Average Trading Volume: 93,214
Technical Sentiment Signal: Buy
Current Market Cap: $65.75M
For detailed information about VANI stock, go to TipRanks’ Stock Analysis page.